7EY Stock Overview
A clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
My Notes
Capture your thoughts, links and company narrative
Kiora Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.79 |
| 52 Week High | US$8.16 |
| 52 Week Low | US$3.20 |
| Beta | -0.28 |
| 1 Month Change | 0% |
| 3 Month Change | 10.30% |
| 1 Year Change | -3.71% |
| 3 Year Change | -99.21% |
| 5 Year Change | -99.67% |
| Change since IPO | -99.97% |
Recent News & Updates
Recent updates
Shareholder Returns
| 7EY | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | -0.2% | -0.4% |
| 1Y | -3.7% | -17.1% | 7.9% |
Return vs Industry: 7EY exceeded the German Pharmaceuticals industry which returned -16% over the past year.
Return vs Market: 7EY underperformed the German Market which returned 4% over the past year.
Price Volatility
| 7EY volatility | |
|---|---|
| 7EY Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 5.5% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 12.1% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 7EY has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 7EY's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 12 | Brian Strem | www.kiorapharma.com |
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials indicated for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. The company is also developing KIO-104, a non-steroidal, immuno-modulatory, small-molecule inhibitor of dihydroorotate dehydrogenase, currently under phase 1b/2a study for the treatment of posterior non-infectious uveitis, as well as under pre-clinical development for the treatment of proliferative vitreoretinopathy; KIO-101, an eye drop for the treatment of ocular presentation of rheumatoid arthritis; and KIO-201, an eye drop for treating patients undergoing photorefractive keratectomy (PRK) surgery for corneal wound repair.
Kiora Pharmaceuticals, Inc. Fundamentals Summary
| 7EY fundamental statistics | |
|---|---|
| Market cap | €9.48m |
| Earnings (TTM) | €2.41m |
| Revenue (TTM) | €14.45m |
3.9x
P/E Ratio0.7x
P/S RatioIs 7EY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 7EY income statement (TTM) | |
|---|---|
| Revenue | US$16.02m |
| Cost of Revenue | US$4.60m |
| Gross Profit | US$11.42m |
| Other Expenses | US$8.75m |
| Earnings | US$2.67m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.90 |
| Gross Margin | 71.30% |
| Net Profit Margin | 16.66% |
| Debt/Equity Ratio | 0% |
How did 7EY perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/09/08 15:01 |
| End of Day Share Price | 2024/06/11 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Kiora Pharmaceuticals, Inc. is covered by 7 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Keay Nakae | Chardan Capital Markets, LLC |
| Yi Chen | H.C. Wainwright & Co. |
| Matthew Kaplan | Ladenburg Thalmann & Company |